#1
prescribed
ranibizumab biosimilar1
THE FIRST AND ONLY FDA-APPROVED BIOSIMILAR INTERCHANGEABLE WITH LUCENTIS®
FOR ALL INDICATIONS2
Created to be similar,
With distinct value
Expect the same efficacy and safety as Lucentis® (ranibizumab injection) with the comprehensive support and savings of CIMERLI®
> 300K DOSES
SHIPPED SINCE LAUNCH*3
*CIMERLI® launched October 3, 2022.
CIMERLI® has attributes identical to Lucentis®4,5:
- Same FDA-approved indications
- Same dosage strengths (0.3 mg & 0.5 mg)
- Same formulation & excipients
- Same amino acid sequence
Discover more about biosimilars and CIMERLI®
Watch Peter Kaiser, MD (Cleveland Clinic Lerner College of Medicine) and Dilsher Dhoot, MD (California Retina Consultants) discuss a range of relevant clinical and industry topics related to biosimilars
Explore the Expert Exchange video library